Indena

#DCATWeek Insights&Trends “As we reflect on the milestones of DCAT Week, it’s impossible to ignore the current context: a time of geopolitical uncertainties. Despite the complexities and challenges the world faces, one thing remains clear: the relentless pursuit of innovation and technological advancement is more important than ever. Indena is contributing with significant technological advancements and capacity expansion, supported by relentless investments. DCAT Week highlights how our pharmaceutical and biotech community continues to evolve, adapt, and progress, despite these uncertainties. Innovation, at its core, is about solving problems, and today, the world faces pressing issues. Yet, what emerges from these challenges is an inspiring wave of creativity and renewed collaboration across borders. Technological advancement plays a pivotal role in overcoming obstacles. From the development of cutting-edge therapies to the use of AI and machine learning in drug discovery, the strides being made in healthcare are revolutionary. At DCAT Week, we witnessed firsthand how the industry is not only navigating the complexities of today's geopolitical landscape but also leveraging technology to drive transformative change. This moment in history calls for collaboration across countries, industries, and areas of expertise. The relationships we cultivate, the knowledge we share, and the partnerships we form are our most valuable resources. It’s clear that technological progress, fueled by collaboration and innovation, will continue to reshape the future of healthcare and beyond.” Daniele Giavini | Managing Director Discover more about Indena’s CDMO: https://lnkd.in/eBbtasNG

#DcatWeek: Insights & Trends “After engaging in extensive discussions and transparent exchanges with our customers and prospects at DCAT 2025, Indena is fully committed to enhancing its services. We aim to address existing identified gaps in the CDMO arena and optimize our processes, allowing us to deliver faster and more effective treatments. Our goal is to bring solutions to orphan diseases and improve cancer therapies, ultimately making a meaningful impact on patients' lives. Indena's CDMO is set to strengthen its presence in the U.S. pharmaceutical market. With a focus on regulatory expertise, cutting-edge ADC technologies, and bespoke services, Indena is ready to partner for supporting the growing demand for high-quality HPAPI manufacturing. By fostering strategic partnerships and maintaining a client-first approach, Indena offers tailored solutions for both large pharma and biotech companies. With a commitment to flexibility, innovation, and quality, Indena is set to drive continued growth in the U.S. market. In addition to discussions with clients and prospects, our colleague Marika Grillo had the pleasure of attending the DCAT Women’s Networking Breakfast with Komal Ahmad as keynote speaker – a two-time Forbes 30 Under 30 honoree and recipient of the Nelson Mandela Humanitarian Award. The event highlighted the importance of determination, leadership, and social impact. Women in the workplace still face challenges, break through stereotypes, and work hard to prove their value every day. Events like this are a powerful reminder of the strength, vision, and essential contributions women bring to every industry.” Bernard Vianès | Global Director CDMO Learn more about Indiana’s CDMO: https://lnkd.in/e4Y8ma4x

#DCATWeek: Insights & Trends “Indena’s expanding synthetic capacity and technology for manufacturing of payloads in Antibody-Drug Conjugates (ADCs) is a prime example of how Contract Development and Manufacturing Organizations (CDMOs) are pivotal in the pharmaceutical sector. This is particularly evident during events like DCAT Week. 1. Expanding Capacity in Synthetic Manufacturing Synthetic expertise is critical for pharmaceutical companies developing small molecules, complex drugs, and highly specialized treatments. Indena’s expansion in synthesis, especially for molecules that require sophisticated chemical approaches, reflects the growing demand for high-quality, reliable production capabilities in this area. A significant expansion has been carried out by Indena, enabling the handling of molecules down to 200 ng/m3 OEL at a hundred kg scale. 2. Focus on payloads for ADCs (Antibody-Drug Conjugates) Antibody-Drug Conjugates (ADCs) represent one of the most promising and sophisticated treatments in oncology and other disease areas. ADCs link a monoclonal antibody with a cytotoxic drug, combining the targeted specificity of antibodies with the potent cell-killing ability of toxins through linkers. Payloads require a highly specialized expertise in both high containment and chemical synthesis, making CDMOs like Indena critical players in the successful development and commercialization of these therapies. Indena is supporting the production of payloads with a further expansion of its kilolabs suites (with reactors up to 100 lt) and freeze-drying capacity. Indena’s expanding synthetic chemistry and ADCs services underscore the increasing relevance of CDMOs at events like DCAT Week, where pharmaceutical and biotech companies are seeking partners to help them navigate the complexities of developing and manufacturing innovative drug products. During DCAT Week, these capabilities are a key talking point as pharmaceutical companies look for solutions to meet the next generation of therapeutic challenges.” Pietro Allegrini | R&D Director Learn more about Indena’s CDMO: https://lnkd.in/enCBWV-h

#DCATWeek: Insights & Trends   “We had a very busy start of DCAT Week today. We discussed numerous new CDMO projects and had updates on ongoing ones, with existing partners and new prospects. DCAT Week offers a unique opportunity to assess the evolution of the pharmaceutical world. Two key messages emerged from this first day: innovation and resilience in the pharmaceutical industry. Innovation remains a key pillar of progress and growth; ADCs continue to increase in relevance, with Indena significantly investing in technology and capacity expansion to develop and manufacture innovative payloads on even larger scale. Resilience - the ability to adapt to global challenges and constraints - is more important than ever. While the pandemic has tested the entire industry, forcing improving in the supply chain resilience, now new global challenges have emerged with trade constraints. The pharmaceutical industry is willing to find collaborative and flexible development and supply solutions, prioritizing the patient and access to innovative treatments. Indena is fully committed to contributing to this future with solutions that address environmental, economic, and health challenges, promoting sustainable growth for the entire pharmaceutical sector.” Stefano Togni | Chief Commercial Officer Discover more about Indena’s CDMO: https://lnkd.in/emAB_i5z

We’re investing in the future of CDMO: new labs, advanced equipment and a focus on ADC payload production. These investments in technology and talent demonstrate our commitment to providing customers receive with competitive and customized CDMO solutions. Read the full press release: https://lnkd.in/eQTNq-9p

#FoodIngredientsChina, the leading international trade show for food additives and ingredients, is almost here! Connect with us and discover the latest in food additives and ingredients. 📍Booth 3V20/3W21

Meet our very Jonathan Guiter here in Milan at Bio-Europe Spring | March 17-19. #BIOEuropeSpring

Join Elisabetta Frattini | Head of Scientific Communication and LCM at #NTCEUROPE2025 in Madrid (IFEMA) to explore the science behind botanical solutions for mental acuity and mood. Don’t miss her presentation today at 13:40 in Seminar Theatre!

#DCATWeek is less than two weeks away! Join us at the Benjamin Hotel in New York City. Schedule your meeting today 👉 https://lnkd.in/eEKCp4iB

#WorldADCLondon is here! Gain valuable insights from our experts Jonathan Guiter | Business Development Manager CDMO and Luca Domenighini | R&D Researcher. 📍Booth 28